Psilocybin enters German psychiatry as a clinical milestone for mental health

Germany’s decision to allow psilocybin therapy for treatment-resistant depression under a compassionate use policy marks a potential shift in European psychiatric drug policy. The model is described as clinician-led, with licensed psychiatrists empowered to make case-by-case decisions without individual applications, paired with oversight from public health authorities. OVID Clinic in Berlin is presented as the program lead, co-founded by psychiatrist Dr. Andrea Jungaberle and researcher and author Dr. Henrik Jungaberle, with ties to the MIND Foundation. The program is framed as integrative and multi-professional, combining structured preparation and integration with somatic and psychiatric input. The article positions psilocybin as a molecule aimed at rapid, durable reductions in depressive symptoms, especially for patients who have not responded to conventional treatments, and situates the German move alongside other European regulatory pathways for psychedelic access.